MGMT and glioblastoma: While this multi-modal therapy has brought a modest overall survival benefit in patients with temozolomide (TMZ)-treatable methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter, it confers little benefit in the 50% of GBM patients with an unmethylated MGMT promoter [2].